A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary

Abstract Cancers of Unknown Primary (CUP) remains a diagnostic and therapeutic challenge due to biological heterogeneity and poor responses to standard chemotherapy. Predicting tissue-of-origin (TOO) molecularly could help refine this diagnosis, with tissue acquisition barriers mitigated via liquid...

תיאור מלא

מידע ביבליוגרפי
Main Authors: Alicia-Marie Conway, Simon P. Pearce, Alexandra Clipson, Steven M. Hill, Francesca Chemi, Dan Slane-Tan, Saba Ferdous, A. S. Md Mukarram Hossain, Katarzyna Kamieniecka, Daniel J. White, Claire Mitchell, Alastair Kerr, Matthew G. Krebs, Gerard Brady, Caroline Dive, Natalie Cook, Dominic G. Rothwell
פורמט: Article
שפה:English
יצא לאור: Nature Portfolio 2024-04-01
סדרה:Nature Communications
גישה מקוונת:https://doi.org/10.1038/s41467-024-47195-7
תיאור
סיכום:Abstract Cancers of Unknown Primary (CUP) remains a diagnostic and therapeutic challenge due to biological heterogeneity and poor responses to standard chemotherapy. Predicting tissue-of-origin (TOO) molecularly could help refine this diagnosis, with tissue acquisition barriers mitigated via liquid biopsies. However, TOO liquid biopsies are unexplored in CUP cohorts. Here we describe CUPiD, a machine learning classifier for accurate TOO predictions across 29 tumour classes using circulating cell-free DNA (cfDNA) methylation patterns. We tested CUPiD on 143 cfDNA samples from patients with 13 cancer types alongside 27 non-cancer controls, with overall sensitivity of 84.6% and TOO accuracy of 96.8%. In an additional cohort of 41 patients with CUP CUPiD predictions were made in 32/41 (78.0%) cases, with 88.5% of the predictions clinically consistent with a subsequent or suspected primary tumour diagnosis, when available (23/26 patients). Combining CUPiD with cfDNA mutation data demonstrated potential diagnosis re-classification and/or treatment change in this hard-to-treat cancer group.
ISSN:2041-1723